Cart
sales@molnova.com
B2
CAS No. 115687-05-3
B2( CPNQ | Linazolamide intermediate B impurity 2 | 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline )
Catalog No. M27605 CAS No. 115687-05-3
B2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 222 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 536 | In Stock |
|
| 100MG | 777 | In Stock |
|
| 500MG | 1548 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameB2
-
NoteResearch use only, not for human use.
-
Brief DescriptionB2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
-
DescriptionB2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease.
-
In Vitro——
-
In Vivo——
-
SynonymsCPNQ | Linazolamide intermediate B impurity 2 | 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
-
PathwayOthers
-
TargetOther Targets
-
RecptorGABAB
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number115687-05-3
-
Formula Weight396.83
-
Molecular FormulaC20H17ClN4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (126.00 mM)
-
SMILES[O-][N+](=O)c1ccc(N2CCN(CC2)C(=O)c2ccc(Cl)cc2)c2cccnc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Q Gillani, et al. CGP 35348, GABA B receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. Biomed Res Int.?2014;2014:295215.
molnova catalog
related products
-
ETHYL 3,5-DIHYDROXYB...
ETHYL 3,5-DIHYDROXYBENZOATE is a natural product.?It inhibits human carbonic anhydrase 2.
-
TIC10
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
-
Compound C108
Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2). Compound C108 can be used in studies about breast tumors and esophageal squamous cell carcinoma.
